NeuroMetrix Inc. (NASDAQ: NURO) To Use Quell Technology in Studying TENS in NMSOD patients

July 16, 2021

NeuroMetrix Inc. (NASDAQ: NURO) has announced they will use Quell tech in a randomized double-blinded, sham-controlled study to establish that transcutaneous electrical nerve stimulation (TENS) is an acceptable, feasible, and effective pain relief method in NMOSD patients. Michael Levy, the director, NMO Clinical & Research laboratory, Massachusetts General Hospital, will be the study’s principal investigator.  NMSOD can lead to vision loss and paralysis  NMSOD is a chronic relapsing autoimmune disease…